My question for you is, based on all the available data generated in the HELIOS-B study, combined with the Nucresiran trial data currently being generated, is it possible that the FDA could allow for an accelerated submission/approval for the ATTR-CM indication
Yes, absolute patient safety is our highest priority
In general, patient reports indicate they do
combined with the impact of gastrointestinal reactions on the absorption and adherence of oral contraceptives, the risk is further amplified, particularly during the initiation or dose-escalation phases of tirzepatide (161, 162, 169)
For those looking for an alternative appetite suppressant to weight loss injections, Phentermine appetite suppressant medication may be an option